Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
2013 · The Lancet Oncology · 597 citations
https://doi.org/10.1016/s1470-2045(13)70549-7
H
Hugo Ford
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
54
Papers
2.1K
Citations
20
h-index
27
i10-index
Hugo Ford is an academic researcher from Cambridge University Hospitals NHS Foundation Trust. The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Colorectal Cancer Treatments and Studies & Esophageal Cancer Research and Treatment. The author has an h-index of 20, co-authored 46 publications.
Papers by this author
worksTrimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
2023 · The Lancet. Gastroenterology & hepatology · 155 citations
https://doi.org/10.1016/s2468-1253(23)00243-1
Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma
2000 · British Journal of Cancer · 26 citations
https://doi.org/10.1054/bjoc.2000.1192
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
2015 · British Journal of Cancer · 23 citations
https://doi.org/10.1038/bjc.2015.342
1401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)
2024 · Annals of Oncology · 16 citations
https://doi.org/10.1016/j.annonc.2024.08.1467
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat